UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
UBS analyst Alice Nettleton initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $184.
UBS analyst Alice Nettleton initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $184.